- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04721418
Aberrant Synaptic Plasticity in Cocaine Use Disorder: A 11C-UCB-J PET Study
October 2, 2023 updated by: Yale University
The purpose of this research study is to measure synaptic density in the brain comparing individuals with cocaine use disorder to healthy controls.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Detailed Description
Healthy controls (HC) will be studied as outpatient and undergo one MRI and one 11C-UCB-J PET scan along with neurocognitive tasks.
Individuals with Cocaine Use Disorder (CUD) will complete the study as inpatients on our unit and undergo one MRI and two 11C-UCB-J PET scan along with neurocognitive tasks.
Cocaine users will be asked to complete outpatient follow-ups twice a week for up to nine weeks following their inpatient stay.
Study Type
Observational
Enrollment (Estimated)
80
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Marcella Mignosa, MD
- Phone Number: 203 974 7557
- Email: marcella.mignosa@yale.edu
Study Locations
-
-
Connecticut
-
New Haven, Connecticut, United States, 06519
- Recruiting
- Connecticut Mental Health Center
-
Contact:
- Gustavo Angarita, MD
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
21 years to 60 years (Adult)
Accepts Healthy Volunteers
Yes
Sampling Method
Probability Sample
Study Population
One group will have current Cocaine Use Disorder, the other group will be Healthy Controls
Description
Inclusion Criteria:
- Age 21-60 years
- Physically healthy by medical history, physical, neurological, ECG and laboratory examinations
- For females, a negative serum pregnancy test
- For CUD: DSM-5 criteria for Cocaine Use Disorder and positive urine toxicology showing recent use
- For HC: Negative urine toxicology
Exclusion Criteria:
- DSM-5 criteria for other substance use disorders (e.g., alcohol, opiates, sedative hypnotics), except for nicotine
- A primary DSM-5 Axis I major psychiatric disorder (e.g., schizophrenia, bipolar disorder, major depression, etc.) as determined by the Structured Clinical Interview for DSM-5 (SCID-5)
- A history of significant and/or uncontrolled medical or neurological illness
- Current use of psychotropic and/or potentially psychoactive prescription medications
- Medical contraindications to MRI procedure
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Cross-Sectional
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Healthy Control
|
11C-UCB-J PET scan
|
Cocaine Use Disorder
|
11C-UCB-J PET scan
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Between-group (CUD vs. HC) comparisons in ACC.
Time Frame: CUD: After 3 weeks of inpatient abstinence. HC: At baseline as outpatient.
|
Between-group comparisons of the fP-corrected total volume of distribution (VT/fP) in ACC.
|
CUD: After 3 weeks of inpatient abstinence. HC: At baseline as outpatient.
|
Between-group (CUD vs. HC) comparisons in vmPFC.
Time Frame: CUD: After 3 weeks of inpatient abstinence. HC: At baseline as outpatient.
|
Between-group comparisons of the fP-corrected total volume of distribution (VT/fP) in vmPFC.
|
CUD: After 3 weeks of inpatient abstinence. HC: At baseline as outpatient.
|
Between-group (CUD vs. HC) comparisons in mOFC.
Time Frame: CUD: After 3 weeks of inpatient abstinence. HC: At baseline as outpatient.
|
Between-group comparisons of the fP-corrected total volume of distribution (VT/fP) in mOFC.
|
CUD: After 3 weeks of inpatient abstinence. HC: At baseline as outpatient.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Within subjects (CUD group) comparisons in ACC.
Time Frame: Baseline versus 3 weeks after.
|
Within subjects (CUD group) comparisons (i.e., baseline/pre-abstinence vs. after 3 weeks of inpatient abstinence) of the fP-corrected total volume of distribution (VT/fP) in ACC.
|
Baseline versus 3 weeks after.
|
Within subjects (CUD group) comparisons in vmPFC.
Time Frame: Baseline versus 3 weeks after.
|
Within subjects (CUD group) comparisons (i.e., baseline/pre-abstinence vs. after 3 weeks of inpatient abstinence) of the fP-corrected total volume of distribution (VT/fP) in vmPFC.
|
Baseline versus 3 weeks after.
|
Within subjects (CUD group) comparisons in mOFC.
Time Frame: Baseline versus 3 weeks after.
|
Within subjects (CUD group) comparisons (i.e., baseline/pre-abstinence vs. after 3 weeks of inpatient abstinence) of the fP-corrected total volume of distribution (VT/fP) in mOFC.
|
Baseline versus 3 weeks after.
|
Between-group (CUD vs. HC) of volume of distribution comparisons in ACC.
Time Frame: CUD: After 3 weeks of inpatient abstinence. HC: At baseline as outpatient.
|
Between-group comparisons of volume of distribution (VT) in ACC.
|
CUD: After 3 weeks of inpatient abstinence. HC: At baseline as outpatient.
|
Between-group (CUD vs. HC) of volume of distribution comparisons in vmPFC.
Time Frame: CUD: After 3 weeks of inpatient abstinence. HC: At baseline as outpatient.
|
Between-group comparisons of volume of distribution (VT) in vmPFC.
|
CUD: After 3 weeks of inpatient abstinence. HC: At baseline as outpatient.
|
Between-group (CUD vs. HC) of volume of distribution comparisons in mOFC.
Time Frame: CUD: After 3 weeks of inpatient abstinence. HC: At baseline as outpatient.
|
Between-group comparisons of volume of distribution (VT) in mOFC.
|
CUD: After 3 weeks of inpatient abstinence. HC: At baseline as outpatient.
|
Between-group (CUD vs. HC) comparisons of binding potential in ACC.
Time Frame: CUD: After 3 weeks of inpatient abstinence. HC: At baseline as outpatient.
|
Between-group comparisons of binding potential (BPND) in ACC.
|
CUD: After 3 weeks of inpatient abstinence. HC: At baseline as outpatient.
|
Between-group (CUD vs. HC) comparisons of binding potential in vmPFC.
Time Frame: CUD: After 3 weeks of inpatient abstinence. HC: At baseline as outpatient.
|
Between-group comparisons of binding potential (BPND) in vmPFC.
|
CUD: After 3 weeks of inpatient abstinence. HC: At baseline as outpatient.
|
Between-group (CUD vs. HC) comparisons of binding potential in mOFC.
Time Frame: CUD: After 3 weeks of inpatient abstinence. HC: At baseline as outpatient.
|
Between-group comparisons of binding potential (BPND) in mOFC.
|
CUD: After 3 weeks of inpatient abstinence. HC: At baseline as outpatient.
|
Between-group (CUD vs. HC) comparisons of gray matter volume in ACC.
Time Frame: CUD: After 3 weeks of inpatient abstinence. HC: At baseline as outpatient.
|
Between-group comparisons of gray matter volume (GMV) in ACC.
|
CUD: After 3 weeks of inpatient abstinence. HC: At baseline as outpatient.
|
Between-group (CUD vs. HC) comparisons of gray matter volume in vmPFC.
Time Frame: CUD: After 3 weeks of inpatient abstinence. HC: At baseline as outpatient.
|
Between-group comparisons of gray matter volume (GMV) in vmPFC.
|
CUD: After 3 weeks of inpatient abstinence. HC: At baseline as outpatient.
|
Between-group (CUD vs. HC) comparisons of gray matter volume in mOFC.
Time Frame: CUD: After 3 weeks of inpatient abstinence. HC: At baseline as outpatient.
|
Between-group comparisons of gray matter volume (GMV) in mOFC.
|
CUD: After 3 weeks of inpatient abstinence. HC: At baseline as outpatient.
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
July 20, 2021
Primary Completion (Estimated)
June 1, 2026
Study Completion (Estimated)
June 1, 2026
Study Registration Dates
First Submitted
January 14, 2021
First Submitted That Met QC Criteria
January 21, 2021
First Posted (Actual)
January 22, 2021
Study Record Updates
Last Update Posted (Actual)
October 3, 2023
Last Update Submitted That Met QC Criteria
October 2, 2023
Last Verified
October 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2000029552
- 1R01DA052454-01A1 (U.S. NIH Grant/Contract)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cocaine Use Disorder
-
New York State Psychiatric InstituteNational Institute on Drug Abuse (NIDA); Columbia UniversityNot yet recruitingCocaine Use Disorder | Cocaine Dependence | Cocaine Use | Cocaine Use Disorder, Moderate | Cocaine Use Disorder, Severe
-
Christopher D. VerricoNot yet recruiting
-
Virginia Polytechnic Institute and State UniversityCarilion Clinic; Arizona State UniversityRecruiting
-
Joshua A. Lile, Ph.D.National Institute on Drug Abuse (NIDA)Recruiting
-
Stalicla SANational Institute on Drug Abuse (NIDA)Recruiting
-
William StoopsNational Institute on Drug Abuse (NIDA)Recruiting
-
William StoopsNational Institute on Drug Abuse (NIDA)Completed
-
William StoopsNational Institute on Drug Abuse (NIDA)Completed
-
Yale UniversityNational Institute on Drug Abuse (NIDA)CompletedCocaine Use DisorderUnited States
Clinical Trials on 11C-UCB-J
-
Alkermes, Inc.University Medical Center Groningen; Amsterdam UMC, location VUmc; QPS Netherlands...CompletedHealthy | Alzheimer DiseaseNetherlands
-
Davidzon, Guido, M.D.Stanford UniversitySuspended
-
Yale UniversityNational Center for Complementary and Integrative Health (NCCIH)RecruitingBehavior, HealthUnited States
-
Yale UniversityNational Institute on Drug Abuse (NIDA)Recruiting
-
Universitaire Ziekenhuizen KU LeuvenCHDI Foundation, Inc.Not yet recruiting
-
Davidzon, Guido, M.D.Weston Havens FoundationRecruiting
-
Centre Hospitalier St AnneRoche Pharma AGNot yet recruitingAlzheimer DiseaseFrance
-
Yale UniversityNational Institute on Drug Abuse (NIDA); National Institute of Mental Health...RecruitingHealthy | Bipolar Disorder | Major Depressive DisorderUnited States
-
Yale UniversityNational Institute of Mental Health (NIMH); National Institutes of Health (NIH)RecruitingHealthy | HIV Dementia | HIV Associated Neurocognitive Disorder | HIV EncephalitisUnited States
-
UCB PharmaYale University; PRA Health SciencesCompleted